Acesion Pharma appoints experienced clinical leader Christina Sylvest as SVP Acute Cardioversion

Acesion Pharma appoints experienced clinical leader Christina Sylvest as SVP Acute Cardioversion

Date
August 5, 2016

COPENHAGEN, Denmark

Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Christina Sylvest, MSc Pharm, as Senior Vice President Acute Cardioversion.

Read the news release from Acesion Pharma.